Geneos Wealth Management’s Ascendis Pharma A/S ASND Stock Holding History

Geneos Wealth Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-129	Closed	-$22.3K	–	2525
2025 Q2	$22.3K	Buy	129 +112	+659%	+$18.2K	﹤0.01%	1979
2025 Q1	$51.4K	Sell	17 -59	-78%	-$8.43K	﹤0.01%	1912
2024 Q4	$10.5K	Buy	76 +1	+1%	+$131	﹤0.01%	2037
2024 Q3	$11.2K	Buy	+75	New	+$10.1K	﹤0.01%	1796
2021 Q2	–	Sell	-1,160	Closed	-$168K	–	2859
2021 Q1	$168K	Buy	+1,160	New	+$176K	﹤0.01%	1053

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geneos Wealth Management's ASND Position: Q3 2025 in Review

Geneos Wealth Management sold out of Ascendis Pharma A/S (ASND) in Q3 2025, closing a stake of 129 shares — an estimated $22.3K sold.

Geneos Wealth Management first reported a position in ASND in Q1 2021 and held it in 5 quarters. The position peaked at $168K in Q1 2021. 279 funds tracked by Wall St. Rank hold ASND as of Q3 2025.

Geneos Wealth Management reported no remaining Ascendis Pharma A/S position as of Q3 2025 after selling out during the quarter.
Geneos Wealth Management sold 129 Ascendis Pharma A/S shares in Q3 2025, an estimated $22.3K.
Geneos Wealth Management first reported a position in Ascendis Pharma A/S in Q1 2021 and held it in 5 quarters.
Geneos Wealth Management's Ascendis Pharma A/S position peaked at $168K in Q1 2021.
279 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.